AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus persistence after 1 year
Number of subjects: 405
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus persistence after 3 years
Number of subjects: 405
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy attendance after 1 year
Number of subjects: 405
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy attendance after 3 years
Number of subjects: 405
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologically confirmed cervical intraepithelial lesions grade 2 or worse after 1 year
Number of subjects: 405
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologically confirmed cervical intraepithelial lesions grade 2 or worse after 3 years
Number of subjects: 405
Study 31585095 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus genotyping
Number of subjects: 405
Study 31946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 1 ng/ml
Number of subjects: 26
Study 31946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 3 ng/ml
Number of subjects: 26
Study 31946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 5 ng/ml
Number of subjects: 26
Study 31946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi)
Number of subjects: 26
Study 28142083 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention
Number of subjects: 54
Study 28142083 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 54
Study 26433886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients with fistula
Number of subjects: 38
Study 26433886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients without fistula
Number of subjects: 38
Study 26433886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients (both groups)
Number of subjects: 38
Study 26433886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients with fistulas
Number of subjects: 38
Study 26433886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients without fistulas
Number of subjects: 38
Study 26433886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 38
Study 23371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented feedback on jumping (AF)
Number of subjects: 37
Study 23371471 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 37
Study 20965755 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN (0.9 mg sublingual)
Number of subjects: 28
Study 20965755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20965755 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 19923521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 L crystalloid (Hartman's solution)
Number of subjects: 60
Study 19923521 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 L of 6% w/v hydroxyethyl starch (HES) solution (HES 0.5)
Number of subjects: 60
Study 19923521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of 6% w/v HES solution (HES 1.0)
Number of subjects: 60
Study 19923521 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study 17199235 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 5 mg/day
Number of subjects: 579
Study 17199235 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 10 mg/day
Number of subjects: 579
Study 17199235 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil
Number of subjects: 579
Study 15129975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-matrix formulation F-1 (30% ibuprofen, 35% ethyl cellulose, 35% hydroxypropyl methylcellulose)
Number of subjects: 9
Study 15129975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-matrix formulation F-2 (60% ibuprofen, 20% ethyl cellulose, 20% xanthan gum)
Number of subjects: 9
Study 15129975 — intervention group
Group type: COMPARATOR
Intervention: Commercially available sustained release product (Ibu-slow)
Number of subjects: 9
Study 11313163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg/day
Number of subjects: 10
Study 9140209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot condition (89.6 degrees C)
Number of subjects: 16
Study 9140209 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (13.7 degrees C)
Number of subjects: 16
Study 7943695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 micrograms
Number of subjects: 150
Study 7943695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 micrograms
Number of subjects: 150
Study 7943695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 10 micrograms
Number of subjects: 150
Study 7943695 — intervention group
Group type: COMPARATOR
Intervention: Control (0.125% bupivacaine with adrenaline)
Number of subjects: 150
Study 3282846 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for four weeks
Number of subjects: 61
Study 3282846 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for eight weeks
Number of subjects: 61
Study 3282846 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily for four weeks
Number of subjects: 61
Study 3282846 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily for eight weeks
Number of subjects: 61
Study 30738417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydraulic expansion
Number of subjects: 190
Study 30738417 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 190
Study 31192555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat porridge (70 grams daily for 4 weeks)
Number of subjects: 0
Study 31192555 — intervention group
Group type: COMPARATOR
Intervention: Rice porridge (4 weeks)
Number of subjects: 0
Study 27495344 — intervention group
Group type: COMPARATOR
Intervention: TAPP repair
Number of subjects: 160
Study 27495344 — intervention group
Group type: COMPARATOR
Intervention: TEP repair
Number of subjects: 160
Study 27495344 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair (both TEP and TAPP)
Number of subjects: 160
Study 25167799 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (PAC) - proton pump inhibitor with amoxicillin and clarithromycin twice a day for 7 days
Number of subjects: 112
Study 25167799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase combined with standard triple therapy (PACE) - pronase (20,000 tyrosine units) with proton pump inhibitor, amoxicillin, and clarithromycin twice a day for 7 days
Number of subjects: 112
Study 23219286 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue tamoxifen to 10 years
Number of subjects: 6846
Study 21715572 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day, titrated to 100 mg/day after 6 weeks
Number of subjects: 32
Study 21715572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no losartan)
Number of subjects: 32
Study 21715572 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 32
Study 18304285 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 1029
Study 18304285 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP education
Number of subjects: 1029
Study 18304285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCP and patient education
Number of subjects: 1029
Study 18304285 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1029
Study 18304285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 1029
Study 18304285 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (general)
Number of subjects: 1029
Study 16242256 — intervention group
Group type: EXPERIMENTAL
Intervention: 76 Gy in 38 fractions (Arm I)
Number of subjects: 100
Study 16242256 — intervention group
Group type: COMPARATOR
Intervention: 70.2 Gy in 26 fractions (Arm II)
Number of subjects: 100
Study 12705512 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg slow-release caffeine
Number of subjects: 12
Study 12705512 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min. nap
Number of subjects: 12
Study 10905362 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC 400 regimen (400 mg clarithromycin)
Number of subjects: 175
Study 10905362 — intervention group
Group type: COMPARATOR
Intervention: LAC 800 regimen (800 mg clarithromycin)
Number of subjects: 175
Study 8833461 — intervention group
Group type: COMPARATOR
Intervention: Positive control (skin irritant substance or product)
Number of subjects: 26
Study 8833461 — intervention group
Group type: COMPARATOR
Intervention: Negative control (compound with low irritant potential)
Number of subjects: 26
Study 8833461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber scarification test
Number of subjects: 26
Study 8833461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-individual variation
Number of subjects: 26
Study 1418278 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 1418278 — intervention group
Group type: COMPARATOR
Intervention: Lytic solution
Number of subjects: 60
Study 3882611 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 240 mg I/ml
Number of subjects: 0
Study 3882611 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 300 mg I/ml
Number of subjects: 0
Study 3882611 — intervention group
Group type: COMPARATOR
Intervention: Meglumine‐Ca metrizoate 200 mg I/ml
Number of subjects: 0
Study 31929374 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg IV ibuprofen administered every 6 hours for a total of 8 doses within 48 hours
Number of subjects: 99
Study 31929374 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every 6 hours for a total of 8 doses within 48 hours
Number of subjects: 99
Study 30088971 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Supports intervention (emotional support, communication support, decisional support, anticipatory grief support)
Number of subjects: 300
Study 30088971 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Supports intervention
Number of subjects: 300
Study 30088971 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 300
Study 26250833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg every 12 hours for 48 weeks
Number of subjects: 213
Study 26250833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 26276068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based and telemonitoring guided home-based exercise training (CRT-Ex group) 5 times a week for 8 weeks.
Number of subjects: 52
Study 26276068 — intervention group
Group type: COMPARATOR
Intervention: Hospital rehabilitation without a training program after discharge (CRT-Control group).
Number of subjects: 52
Study 23218065 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive handling (gentle handling with soft voices, slow movements, patting)
Number of subjects: 40
Study 23218065 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative handling (rough handling with rough voices, rapid movements, pushing)
Number of subjects: 40
Study 23218065 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive handling
Number of subjects: 40
Study 23218065 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative handling
Number of subjects: 40
Study 21349192 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone and amiloride
Number of subjects: 1200
Study 21349192 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 1200
Study 19047545 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma questionnaire and lung function testing
Number of subjects: 224
Study 19047545 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentages of predicted FEV(1) and predicted FEF(25%-75%) and FEV(1)/FVC
Number of subjects: 224
Study 19047545 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding FEV(1)/FVC to symptom history
Number of subjects: 224
Study 16571371 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0
Study 16571371 — intervention group
Group type: COMPARATOR
Intervention: Reduction of laser intensity
Number of subjects: 0
Study 15137554 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended stroke unit service (extended service)
Number of subjects: 62
Study 15137554 — intervention group
Group type: COMPARATOR
Intervention: Ordinary stroke unit service (ordinary service)
Number of subjects: 62
Study 10769522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous drainage
Number of subjects: 26
Study 10769522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous drainage for simple abscesses
Number of subjects: 26
Study 10769522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous drainage for complex abscesses
Number of subjects: 26
Study 9351734 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement approach using clinical and exercise test variables
Number of subjects: 1080
Study 9351734 — intervention group
Group type: EXPERIMENTAL
Intervention: Three prediction equations (developed by the study and two others)
Number of subjects: 1080
Study 8155409 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic trabecular pattern observation
Number of subjects: 0
Study 8155409 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal status
Number of subjects: 0
Study 2940499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 20
Study 2940499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29304083 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal STIs (CT, TP, NG, CMV)
Number of subjects: 899
Study 29304083 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CMV
Number of subjects: 899
Study 29304083 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant congenital CMV
Number of subjects: 899
Study 26896559 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupedal gait training programme
Number of subjects: 22
Study 26896559 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 24999369 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar therapy (6 sessions of 30 minutes each)
Number of subjects: 0
Study 24999369 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control group)
Number of subjects: 0
Study 22538186 — intervention group
Group type: EXPERIMENTAL
Intervention: High incentive with sadness prime
Number of subjects: 62
Study 22538186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low incentive with sadness prime
Number of subjects: 62
Study 22538186 — intervention group
Group type: EXPERIMENTAL
Intervention: High incentive with anger prime
Number of subjects: 62
Study 22538186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low incentive with anger prime
Number of subjects: 62
Study 20494464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral professional care with mucosal care
Number of subjects: 50
Study 20494464 — intervention group
Group type: COMPARATOR
Intervention: Oral professional care without mucosal care
Number of subjects: 50
Study 18831889 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg 0.5% bupivacaine plus 25 microg fentanyl (group BF)
Number of subjects: 35
Study 18831889 — intervention group
Group type: COMPARATOR
Intervention: 5 mg 0.5% bupivacaine alone (group B)
Number of subjects: 35
Study 15882458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic stethoscope
Number of subjects: 48
Study 15882458 — intervention group
Group type: COMPARATOR
Intervention: Conventional acoustic stethoscope
Number of subjects: 48
Study 11708710 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 16
Study 11708710 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 16
Study 9223885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose midazolam (MZ) administered i.v. at doses of 0, 0.03, 0.06 mg.kg‐1
Number of subjects: 70
Study 8132916 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision combined with individualized care (Experimental Ward)
Number of subjects: 38
Study 8132916 — intervention group
Group type: COMPARATOR
Intervention: Control Ward (no intervention)
Number of subjects: 38
Study 2957057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis followed by immediate coronary angioplasty
Number of subjects: 533
Study 2957057 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533
Study 2957057 — intervention group
Group type: EXPERIMENTAL
Intervention: Late patency of the infarct related vessel postthrombolytic therapy without angioplasty
Number of subjects: 533
Study 2957057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined procedure of thrombolysis and angioplasty (group B)
Number of subjects: 533
Study 29424674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar corset usage
Number of subjects: 54
Study 29424674 — intervention group
Group type: COMPARATOR
Intervention: No lumbar corset usage (Control)
Number of subjects: 54
Study 26643541 — intervention group
Group type: EXPERIMENTAL
Intervention: NSI-189 40 mg q.d. (n=6)
Number of subjects: 24
Study 26643541 — intervention group
Group type: EXPERIMENTAL
Intervention: NSI-189 40 mg b.i.d. (n=6)
Number of subjects: 24
Study 26643541 — intervention group
Group type: EXPERIMENTAL
Intervention: NSI-189 40 mg t.i.d. (n=6)
Number of subjects: 24
Study 26643541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2)
Number of subjects: 24
Study 23693155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led smoking cessation intervention with at least three support sessions (during hospital stay, post-discharge, and within one month post-discharge) and free smoking cessation medications during hospital stay and for at least one week after discharge.
Number of subjects: 0
Study 23693155 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by the hospital.
Number of subjects: 0
Study 21300711 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 20025727 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention program 'Smoke-free Kids' consisting of five printed activity modules designed to improve parenting skills specific to smoking prevention and parent-child communication regarding smoking.
Number of subjects: 0
Study 20025727 — intervention group
Group type: COMPARATOR
Intervention: Control condition with solely information on smoking and tobacco use.
Number of subjects: 0
Study 17038074 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for AMD (n=12)
Number of subjects: 32
Study 17038074 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (n=20)
Number of subjects: 32
Study 12782168 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity tests using the Vistech contrast sensitivity test chart (VCTS 6500)
Number of subjects: 0
Study 11860915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 0
Study 11860915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9375336 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (100 mg atenolol) before training
Number of subjects: 16
Study 9375336 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (100 mg atenolol) after training
Number of subjects: 16
Study 9375336 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control before training
Number of subjects: 16
Study 9375336 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control after training
Number of subjects: 16
Study 8298585 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 3 g fosfomycin trometamol
Number of subjects: 231
Study 8298585 — intervention group
Group type: COMPARATOR
Intervention: Seven days of nitrofurantoin 50 mg four times daily
Number of subjects: 231
Study 3236329 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 2.5 mg once daily
Number of subjects: 20
Study 3236329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29687553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on six variables (age, alpha fetoprotein, neutrophil-to-lymphocyte ratio, international normalized ratio, tumour size, tumour number)
Number of subjects: 1135
Study 29687553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 1135
Study 28473158 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum (CCH)
Number of subjects: 50
Study 28473158 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous needle fasciotomy (PNF)
Number of subjects: 50
Study 26191947 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min SFAS session
Number of subjects: 97
Study 26191947 — intervention group
Group type: COMPARATOR
Intervention: Education control session
Number of subjects: 97
Study 24320900 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study 24320900 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ) + amoxicillin (AMX) for 14 days
Number of subjects: 30
Study 21867369 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning school schedule (07:30 - 12:00)
Number of subjects: 379
Study 21867369 — intervention group
Group type: COMPARATOR
Intervention: Afternoon school schedule (13:00 - 17:30)
Number of subjects: 379
Study 19187664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamycin
Number of subjects: 300
Study 19187664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Povidone-iodine
Number of subjects: 300
Study 19187664 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% Povidone-iodine
Number of subjects: 300
Study 19187664 — intervention group
Group type: COMPARATOR
Intervention: All groups (Gentamycin, 0.5% Povidone-iodine, 5.0% Povidone-iodine)
Number of subjects: 300